BioAge Labs, Inc. - Common Stock (NQ:BIOA)

17.29 -1.07 (-5.83%)

Streaming Delayed Price Updated: 2:58 PM EDT, Apr 23, 2026 Add to My Watchlist

Price and Volume

Volume	262,140
Open	18.36
Bid (Size)	17.29 (300)
Ask (Size)	17.38 (100)
Prev. Close	18.36
Today's Range	17.18 - 18.73
52wk Range	3.670 - 24.00
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP

April 21, 2026

From BioAge Labs, Inc.

Via GlobeNewswire

BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference

April 13, 2026

From BioAge Labs, Inc.

Via GlobeNewswire

Performance

YTD	+34.8%	+34.8%
1 Month	-7.2%	-7.2%
3 Month	-14.1%	-14.1%
6 Month	+185.8%	+185.8%
1 Year	+311.7%	+311.7%

More News

BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025

March 24, 2026

From BioAge Labs, Inc.

Via GlobeNewswire

BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 19, 2026

From BioAge Labs, Inc.

Via GlobeNewswire

BioAge Announces Pricing of Upsized $115.0 Million Public Offering

January 21, 2026

From BioAge Labs, Inc.

Via GlobeNewswire

BioAge Announces Proposed Public Offering

January 20, 2026

From BioAge Labs, Inc.

Via GlobeNewswire

BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026

January 20, 2026

From BioAge Labs, Inc.

Via GlobeNewswire

BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk

January 12, 2026

From BioAge Labs, Inc.

Via GlobeNewswire

Tuesday's after hours session: top gainers and losers ↗

January 06, 2026

Via Chartmill

2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole ↗

December 13, 2025

Via The Motley Fool

BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

December 04, 2025

From BioAge Labs, Inc.

Via GlobeNewswire

BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference

November 25, 2025

From BioAge Labs, Inc.

Via GlobeNewswire

BioAge Labs to Present at Jefferies Global Healthcare Conference in London

November 07, 2025

From BioAge Labs, Inc.

Via GlobeNewswire

BioAge Labs Inc (NASDAQ:BIOA) Reports Q3 2025 Earnings with Significant Revenue Beat ↗

November 06, 2025

Via Chartmill

BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates

November 06, 2025

From BioAge Labs, Inc.

Via GlobeNewswire

Citigroup Says This Obesity Drugmaker's Stock Is Now a Buy ↗

November 05, 2025

Via The Motley Fool

Could This Anti-Obesity Drug Biotech Be Poised to Soar in 2026? ↗

October 29, 2025

Via The Motley Fool

BioAge Labs Stock Just Soared. Does It Have More Fuel to Climb Higher? ↗

October 26, 2025

Via The Motley Fool

Here are the top movers in Thursday's session. ↗

October 23, 2025

Via Chartmill

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

October 23, 2025

Via Benzinga

Which stocks are moving on Thursday? ↗

October 23, 2025

Via Chartmill

These stocks are gapping in today's session ↗

October 23, 2025

Via Chartmill

Wondering what's happening in today's pre-market session? ↗

October 23, 2025

Via Chartmill

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

October 23, 2025

Via Benzinga

This Badger Meter Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday ↗

October 22, 2025

Via Benzinga

Frequently Asked Questions

Is BioAge Labs, Inc. - Common Stock publicly traded?

Yes, BioAge Labs, Inc. - Common Stock is publicly traded.

What exchange does BioAge Labs, Inc. - Common Stock trade on?

BioAge Labs, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for BioAge Labs, Inc. - Common Stock?

The ticker symbol for BioAge Labs, Inc. - Common Stock is BIOA on the Nasdaq Stock Market

What is the current price of BioAge Labs, Inc. - Common Stock?

The current price of BioAge Labs, Inc. - Common Stock is 17.29

When was BioAge Labs, Inc. - Common Stock last traded?

The last trade of BioAge Labs, Inc. - Common Stock was at 04/23/26 02:58 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.